Grufity logo
Grufity logo

Latest Bellevue Group AG Stock Portfolio

$4.20Billion | No. of Holdings #155

Bellevue Group AG Performance

2026 Q1-4.67%
YTD-4.67%
2025+20.44%

About Bellevue Group AG and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Bellevue Group AG reported an equity portfolio of $4.2 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Bellevue Group AG are VRTX, ARGX, REGN. The fund has invested 7.2% of it's portfolio in VERTEX PHARMACEUTICALS INC and 5.4% of portfolio in ARGENX SE. <br><br> The fund managers got completely rid off AVIDITY BIOSCIENCES INC (RNA), AMICUS THERAPEUTICS INC (FOLD) and MAZE THERAPEUTICS INC stocks. They significantly reduced their stock positions in NEUROCRINE BIOSCIENCES INC (NBIX), WAVE LIFE SCIENCES LTD (WVE) and IQVIA HLDGS INC (IQV). Bellevue Group AG opened new stock positions in ENLIVEN THERAPEUTICS INC, VAXCYTE INC (PCVX) and DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to ULTRAGENYX PHARMACEUTICAL IN (RARE), CRINETICS PHARMACEUTICALS IN (CRNX) and GILEAD SCIENCES INC (GILD).
Bellevue Group AG Equity Portfolio Value
Last Reported on: 15 May, 2026
$4.20Billion
  as of May 15, 2026

Bellevue Group AG Annual Return Estimates Vs S&P 500

Our best estimate is that Bellevue Group AG made a return of -4.67% in the last quarter. In trailing 12 months, it's portfolio return was 21.22%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
enliven therapeutics inc90,978,000
vaxcyte inc69,191,400
damora therapeutics inc59,518,200
disc medicine inc29,368,500
oruka therapeutics inc24,868,700
monte rosa therapeutics inc20,562,500
livanova plc11,833,900
atrium therapeutics inc3,517,590
New stocks bought by Bellevue Group AG

Additions

Ticker% Inc.
ultragenyx pharmaceutical in92,148
crinetics pharmaceuticals in81,088
gilead sciences inc2,117
regeneron pharmaceuticals1,900
amgen inc1,497
olema pharmaceuticals inc321
cencora inc229
royalty pharma plc190
Additions to existing portfolio by Bellevue Group AG

Reductions

Ticker% Reduced
neurocrine biosciences inc-99.73
wave life sciences ltd-99.65
iqvia hldgs inc-98.21
quest diagnostics inc-98.2
ascendis pharma a/s-97.8
structure therapeutics inc-95.31
labcorp holdings inc-95.06
masimo corp-91.00
Bellevue Group AG reduced stake in above stock

Sold off

Ticker$ Sold
amicus therapeutics inc-152,869,000
avidity biosciences inc-189,772,000
maze therapeutics inc-36,777,700
caredx inc-8,121,360
neogenomics inc-3,272,640
avantor inc-3,166,010
brookdale sr living inc-1,806,720
compass pathways plc-981,477
Bellevue Group AG got rid off the above stocks

Sector Distribution

Bellevue Group AG has about 87.5% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare87.5
Others12.4

Market Cap. Distribution

Bellevue Group AG has about 56.4% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • UNALLOCATED
  • SMALL-CAP
  • MEGA-CAP
  • NANO-CAP
Category%
LARGE-CAP52.8
MID-CAP21.5
UNALLOCATED12.4
SMALL-CAP7.9
MEGA-CAP3.6
NANO-CAP1.8

Stocks belong to which Index?

About 77.7% of the stocks held by Bellevue Group AG either belong to S&P 500 or RUSSELL 2000 index.

  • S&P 500
  • RUSSELL 2000
  • Others
Index%
S&P 50046.1
RUSSELL 200031.6
Others22.3
Top 5 Winners (%)%
TNGX
tango therapeutics inc
109.7 %
TXG
10x genomics inc
29.7 %
EWTX
edgewise therapeutics inc
26.9 %
ALKS
alkermes plc
22.2 %
MASI
masimo corp
20.0 %
Top 5 Winners ($)$
RVMD
revolution medicines inc
57.6 M
TNGX
tango therapeutics inc
38.2 M
SRRK
scholar rock hldg corp
19.5 M
RLAY
relay therapeutics inc
12.0 M
CLDX
celldex therapeutics inc new
11.0 M
Top 5 Losers (%)%
beta bionics inc
-67.0 %
INSP
inspire med sys inc
-43.9 %
PHR
phreesia inc
-43.3 %
CERT
certara inc
-35.3 %
caris life sciences inc
-33.7 %
Top 5 Losers ($)$
VRDN
viridian therapeutics inc
-64.1 M
BSX
boston scientific corp
-49.3 M
ARGX
argenx se
-42.9 M
ISRG
intuitive surgical inc
-32.1 M
ABT
abbott laboratories
-27.9 M

Bellevue Group AG Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Bellevue Group AG

Bellevue Group AG has 155 stocks in it's portfolio. About 41.9% of the portfolio is in top 10 stocks. VRDN proved to be the most loss making stock for the portfolio. RVMD was the most profitable stock for Bellevue Group AG last quarter.

$4.20BTotal Value
195Positions
15 May, 2026Last Reported
Current holdings of Current Stock Holdings of Bellevue Group AG, last reported on 15 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
AFK
Vaneck Etf Trust

Vaneck Etf Trust

AFK
Bellevue Group AG's holding in Vaneck Etf Trust over time
0.01%5,750
$527.7K
0.01%
decreased 62.9 percentreduced
ARGX
Argenx Se

Argenx Se

ARGX
Bellevue Group AG's holding in Argenx Se over time
5.44%313,000
$228.57M
5.44%
decreased 32.23 percentreduced